{"id":"NCT00174447","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031","officialTitle":"Open Extension Study Evaluating The Long Term Efficacy , Safety And Tolerability Of Oral Ziprasidone In The Treatment Of Patients Who Have Successfully Completed The Previous Ziprasidone Study A1281031","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2001-10","primaryCompletion":"2008-10","completion":"2008-10","firstPosted":"2005-09-15","resultsPosted":"2009-11-17","lastUpdate":"2021-03-24"},"enrollment":43,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Ziprasidone","otherNames":[]}],"arms":[{"label":"A1","type":"EXPERIMENTAL"}],"summary":"Open label extension study of Ziprasidone, evaluation of safety of long term use of ziprasidone","primaryOutcome":{"measure":"Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I)","timeFrame":"Baseline, 3 months, 6 months, 1 year, 3 years, 5 years, End of Study [LOCF]","effectByArm":[{"arm":"Ziprasidone","deltaMin":13,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":14,"countries":["France"]},"refs":{"pmids":["21796719","18312045"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1281060&StudyName=Extension%20Study%20of%20Patients%20Successfully%20Treated%20by%20Ziprasidone%20in%20Study%20A1281031%20"]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":43},"commonTop":["Anxiety","Insomnia","Schizophrenia","Depression","Depressed mood"]}}